2-(2-hydroxyphenyl)propanoic acid | 533931-68-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 2-(2-hydroxyphenyl)propanoic acid
• 英文别名: 2-hydroxyphenylpropanoic acid；2-(2-Hydroxyphenyl)propionic acid
• CAS: 533931-68-9
• 化学式: C₉H₁₀O₃
• 分子量: 166.177
• InChiKey: KRHQRJXHSUXNQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2-hydroxyphenyl)propanoic acid 在 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 生成 3-methyl-3H-benzofuran-2-one
  参考文献：
  名称：

  Potential antitumor agents. 63. Structure-activity relationships for side-chain analogs of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid

  摘要：

  A series of 16 analogues of the solid tumor active compound 9-oxo-9H-xanthene-4-acetic acid (XAA), with variations in the acetic acid side chain, have been prepared and evaluated for their ability to cause early haemorrhagic necrosis of colon 38 tumors in mice. The results extend the previous SAR for this class and confirm the necessity for a carboxylic acid group in a fixed disposition with respect to the xanthenone chromophore. None of the compounds showed superior potency to XAA itself, with virtually all alterations in the nature of the anionic center or its geometry with respect to the chromophore greatly reducing or abolishing activity. However, alpha-methylation of the side chain was permissible, and the two enantiomers of 5-methyl-alpha-methyl-XAA were separated and tested. Both were active, but the S-(+) enantiomer was much more dose-potent than the R-(-) enantiomer, in both the in vivo tumor necrosis assay and an in vitro assay measuring the stimulation of nitric oxide production by macrophages. This suggests that the enantiomers have different intrinsic activities, rather than differing in their vivo metabolism.

  DOI：

  10.1021/jm00113a027
• 作为产物：
  描述：

  1-(benzyloxy)-2-(1-chloroethyl)benzene 在 palladium on activated charcoal 氢氧化钾 、 氢气 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 2-(2-hydroxyphenyl)propanoic acid
  参考文献：
  名称：

  Potential antitumor agents. 63. Structure-activity relationships for side-chain analogs of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid

  摘要：

  A series of 16 analogues of the solid tumor active compound 9-oxo-9H-xanthene-4-acetic acid (XAA), with variations in the acetic acid side chain, have been prepared and evaluated for their ability to cause early haemorrhagic necrosis of colon 38 tumors in mice. The results extend the previous SAR for this class and confirm the necessity for a carboxylic acid group in a fixed disposition with respect to the xanthenone chromophore. None of the compounds showed superior potency to XAA itself, with virtually all alterations in the nature of the anionic center or its geometry with respect to the chromophore greatly reducing or abolishing activity. However, alpha-methylation of the side chain was permissible, and the two enantiomers of 5-methyl-alpha-methyl-XAA were separated and tested. Both were active, but the S-(+) enantiomer was much more dose-potent than the R-(-) enantiomer, in both the in vivo tumor necrosis assay and an in vitro assay measuring the stimulation of nitric oxide production by macrophages. This suggests that the enantiomers have different intrinsic activities, rather than differing in their vivo metabolism.

  DOI：

  10.1021/jm00113a027

文献信息

• 4-[(8-Ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome P450RAI inhibitory activity
  申请人：——

  公开号：US20030191181A1

  公开（公告）日：2003-10-09

  Compounds of Formula 1 1 wherein the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.

  公式1的化合物 1 其中，变量在说明书中定义，具有细胞色素P450RAI-1和P450RAI-2的抑制活性，适用于治疗可用视黄酸治疗的哺乳动物疾病，或由生物体的天然视黄酸控制或响应的疾病。包含本发明的化合物的制剂还可以与视黄酸和/或维生素A共同给药，以增强或延长含有视黄酸、维生素A或生物体天然视黄酸的药物的效果。
• 4-[(8-Substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-yl-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity
  申请人：——

  公开号：US20030207937A1

  公开（公告）日：2003-11-06

  Compounds of the formula 1 where the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.

  具有公式1的化合物，其中变量在说明书中定义，具有细胞色素P450RAI-1和P450RAI-2的抑制活性，并且适用于治疗可通过视黄酸治疗的哺乳动物疾病，或由生物体的天然视黄酸控制或响应的疾病。包含本发明的化合物的制剂还可以与视黄酸和/或维生素A共同给药，以增强或延长含有视黄酸、维生素A或生物体天然视黄酸的药物的效果。
• Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A
  申请人：——

  公开号：US20040077721A1

  公开（公告）日：2004-04-22

  vitamin A, or a derivative of vitamin A having vitamin A like activity is co-administered with inhibitors of the CP450RAI1 and/or of CP450RAI2 enzymes for the purpose of treating diseases and conditions in mammals, including humans, which diseases or conditions are prevented, treated, ameliorated, or the onset of which is delayed by administration of retinoid compounds or by the mammalian organism's naturally occurring retinoic acid.

  维生素A，或具有维生素A活性的维生素A衍生物与CP450RAI1和/或CP450RAI2酶的抑制剂共同给药，用于治疗哺乳动物，包括人类的疾病和状况，这些疾病或状况可以通过施用视黄酸化合物或通过哺乳动物机体自然存在的视黄酸来预防、治疗、改善或延迟其发作。
• [EN] AMIDOMETHYL-BIARYL DERIVATIVES COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF<br/>[FR] DÉRIVÉS D'AMINOMÉTHYL-BIARYLE EN TANT QU'INHIBITEURS DU FACTEUR D DU COMPLÉMENT ET LEURS UTILISATIONS
  申请人：NOVARTIS AG

  公开号：WO2016088082A1

  公开（公告）日：2016-06-09

  The present invention provides a compound of formula (I): (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种公式(I)的化合物：(I)一种制造本发明化合物的方法及其治疗用途。本发明进一步提供了一种药物活性剂的组合物和一种药物组合物。
• [EN] CARBONIC ANHYDRASE IX INHIBITOR CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS D'INHIBITEURS D'ANHYDRASE CARBONIQUE IX ET LEURS UTILISATIONS
  申请人：ENDOCYTE INC

  公开号：WO2017161144A1

  公开（公告）日：2017-09-21

  The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors as therapeutics and imaging agents. The present disclosure also relates to the use of targeting conjugates of carbonic anhydrase IX inhibitors in imaging methods and cancer therapy.

  本公开涉及碳酸酐酶IX抑制剂的组合物和方法。本公开还涉及碳酸酐酶IX抑制剂的靶向共轭物作为治疗剂和成像剂。本公开还涉及在成像方法和癌症治疗中使用碳酸酐酶IX抑制剂的靶向共轭物。